Number of suitable people: CDEC discussed the uncertainty in the number of individuals with moderately severe to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are categorised as owning moderate or reasonable condition might have a extreme bleeding